| Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial J Bellmunt, M Hussain, JE Gschwend, P Albers, S Oudard, D Castellano, ... The lancet oncology 22 (4), 525-537, 2021 | 263 | 2021 |
| Testicular cancer, version 2.2020, NCCN clinical practice guidelines in oncology T Gilligan, DW Lin, R Aggarwal, D Chism, N Cost, IH Derweesh, ... Journal of the National Comprehensive Cancer Network 17 (12), 1529-1554, 2019 | 222 | 2019 |
| Muscle-invasive urothelial bladder cancer: an update on systemic therapy H Knollman, JL Godwin, R Jain, YN Wong, ER Plimack, DM Geynisman Therapeutic advances in urology 7 (6), 312-330, 2015 | 203 | 2015 |
| Trends in the cost and use of targeted cancer therapies for the privately insured nonelderly: 2001 to 2011 YCT Shih, F Smieliauskas, DM Geynisman, RJ Kelly, TJ Smith Journal of Clinical Oncology 33 (19), 2190, 2015 | 179 | 2015 |
| Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study NM Chanzá, W Xie, MA Bilen, H Dzimitrowicz, J Burkart, DM Geynisman, ... The lancet oncology 20 (4), 581-590, 2019 | 152 | 2019 |
| The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease T Seeger-Nukpezah, DM Geynisman, AS Nikonova, T Benzing, ... Nature Reviews Nephrology 11 (9), 515-534, 2015 | 134 | 2015 |
| Immune‐related adverse events as a biomarker in non‐melanoma patients treated with programmed cell death 1 inhibitors J Judd, M Zibelman, E Handorf, J O'Neill, C Ramamurthy, S Bentota, ... The oncologist 22 (10), 1232-1237, 2017 | 128 | 2017 |
| Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients with metastatic urothelial cancer MD Galsky, A Mortazavi, MI Milowsky, S George, S Gupta, MT Fleming, ... Journal of Clinical Oncology 38 (16), 1797, 2020 | 125 | 2020 |
| Relationships among financial distress, emotional distress, and overall distress in insured patients with cancer CR Meeker, DM Geynisman, BL Egleston, MJ Hall, KY Mechanic, ... Journal of oncology practice 12 (7), e755-e764, 2016 | 110 | 2016 |
| Adherence to targeted oral anticancer medications DM Geynisman, KE Wickersham Discovery medicine 15 (83), 231, 2013 | 103 | 2013 |
| Characterization of clinical cases of advanced papillary renal cell carcinoma via comprehensive genomic profiling SK Pal, SM Ali, E Yakirevich, DM Geynisman, JA Karam, JA Elvin, ... European urology 73 (1), 71-78, 2018 | 102 | 2018 |
| Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder‐preservation therapy for muscle‐invasive bladder cancer DB Cahn, EA Handorf, EM Ghiraldi, BT Ristau, DM Geynisman, ... Cancer 123 (22), 4337-4345, 2017 | 93 | 2017 |
| Tumor genome analysis includes germline genome: are we ready for surprises? DVT Catenacci, AL Amico, SM Nielsen, DM Geynisman, B Rambo, ... International journal of cancer 136 (7), 1559-1567, 2015 | 88 | 2015 |
| Mutations in renal cell carcinoma C D'Avella, P Abbosh, SK Pal, DM Geynisman Urologic Oncology: Seminars and Original Investigations 38 (10), 763-773, 2020 | 84 | 2020 |
| Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)–tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients … R Nadal, A Amin, DM Geynisman, MH Voss, M Weinstock, J Doyle, ... Annals of Oncology 27 (7), 1304-1311, 2016 | 75 | 2016 |
| Approved checkpoint inhibitors in bladder cancer: which drug should be used when? P Ghatalia, M Zibelman, DM Geynisman, E Plimack Therapeutic advances in medical oncology 10, 1758835918788310, 2018 | 73 | 2018 |
| A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN … NM Hahn, TJ Bivalacqua, AE Ross, GJ Netto, A Baras, JC Park, ... Clinical Cancer Research 23 (12), 3003-3011, 2017 | 68 | 2017 |
| Checkpoint inhibitors for the treatment of renal cell carcinoma P Ghatalia, M Zibelman, DM Geynisman, ER Plimack Current treatment options in oncology 18, 1-14, 2017 | 64 | 2017 |
| Defects in DNA repair genes confer improved long-term survival after cisplatin-based neoadjuvant chemotherapy for muscle-invasive bladder cancer B Miron, JH Hoffman-Censits, F Anari, J O’Neill, DM Geynisman, ... European urology oncology 3 (4), 544-547, 2020 | 62 | 2020 |
| Treatment trends and outcomes for patients with lymph node–positive cancer of the penis SS Joshi, E Handorf, D Strauss, AF Correa, A Kutikov, DYT Chen, ... JAMA oncology 4 (5), 643-649, 2018 | 61 | 2018 |
